FirsthandHealth
medRxiv PreprintsInternational19 November 2026

Additional value of germline genomic scores beyond prostate-specific antigen alone for long-term and near-term prostate cancer risk

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

We evaluated whether germline genomic risk complements prostate-specific antigen (PSA) for prostate cancer early detection. P-CARE integrates a 601-variant polygenic hazard score, family history, and genetic ancestry. Long-term outcomes and clinically significant prostate cancer (csPCa) detection on biopsy were assessed in the Million Veteran Program (MVP), with external validation in the Prostate Cancer Prevention Trial (PCPT). Among 428,512 MVP participants, high versus low P-CARE risk was associated with increased hazards of treatment (HR 3.32) and metastasis (HR 3.32). Among men whose base
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.